tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Omeros (OMER), Atossa Therapeutics (ATOS) and PDS Biotechnology (PDSB)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Omeros (Research Report).

Omeros (OMER)

Needham analyst Serge Belanger maintained a Hold rating on Omeros today. The company’s shares closed last Tuesday at $6.20.

According to 6.4% and a 47.1% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Hold analyst consensus rating for Omeros with a $4.00 average price target.

See today’s best-performing stocks on TipRanks >>

Atossa Therapeutics (ATOS)

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Atossa Therapeutics, with a price target of $4.00. The company’s shares closed last Tuesday at $0.98, close to its 52-week low of $0.84.

According to -40.0% and a 13.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

Currently, the analyst consensus on Atossa Therapeutics is a Moderate Buy with an average price target of $5.75.

PDS Biotechnology (PDSB)

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on PDS Biotechnology, with a price target of $22.00. The company’s shares closed last Tuesday at $5.32, close to its 52-week low of $2.91.

According to 10.4% and a 34.4% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Onconova Therapeutics, and Ayala Pharmaceuticals.

PDS Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $19.25, implying a 274.5% upside from current levels. In a report issued on August 8, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OMER:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More